InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,714.00
(
0.18%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.25
(
0.04%
)
Bitcoin
62,447.74
(
-0.73%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

tripil7z

Send PM Follow Ignore
Followers 684
Posts 17338
Boards Moderated 2
Alias Born 03/28/2011

tripil7z

Re: None

Monday, 08/29/2016 5:41:46 PM

Monday, August 29, 2016 5:41:46 PM

Post# of 97237
$RIGL 2.64 in AH trading


http://ih.advfn.com/p.php?pid=nmona&article=72308840&adw=1126416



SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016. The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results.

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 72149873.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up